PMV Pharmaceuticals Inc. Common Stock (PMVP)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach clinical-stage biotech with Graham's caution: without revenue or earnings, an earnings-based margin of safety is impossible to calculate. PMV Pharmaceuticals reports no revenue in the filed periods I have. It lost $77.7 million in fiscal year 2025, the period ended 2025-12-31; $58.7 million in fiscal year 2024, the period ended 2024-12-31; and $69.0 million in fiscal year 2023, the period ended 2023-12-31. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $18.0 million; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $18.1 million. Trailing free cash flow was -$71.3 million, a -98.8% FCF yield against a $72.2 million market cap at the 2026-10-13 close of $1.35. That is stark: the company appears to burn roughly its entire market value each year. It has no debt (D/E 0.00), and FairStock's P/B is 1.01, so the price is near reported book value. But negative ROE (-70.93%) and ROCE (-42.39%), a Piotroski F-Score of 1/9, and an Altman Z-Score of -3.10 indicate financial fragility and weak fundamental momentum. The key asset is rezatapopt, a Phase 2 p53 Y220C corrector. Positive data could create large optionality; failure would make cash burn the dominant fact. FairStock's Lynch category is none because it has lost money in each of the last four years. This is a speculative pipeline bet, not a Graham defensive value.

In plain English: PMV Pharmaceuticals is a small cancer-drug developer with no product sales. It is testing a pill for cancers linked to a specific gene mutation. The business loses money and burns cash quickly, so although the price is near the value of its net assets on paper, it is hard to call cheap using ordinary business numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer